Cargando…
Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database
PURPOSE: To develop the clinical calculator for mortality of patients with metastatic renal cell carcinoma (mRCC) using Korean Renal Cancer Study Group (KRoCS) database. MATERIALS AND METHODS: Data from 1,115 patients with mRCC treated in 4 hospitals joining KRoCS between 1993 and 2016 were pooled....
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Urological Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189103/ https://www.ncbi.nlm.nih.gov/pubmed/32377601 http://dx.doi.org/10.4111/icu.2020.61.3.260 |
_version_ | 1783527438816378880 |
---|---|
author | Park, Jae Young Tae, Bum Sik Jeong, Chang Wook Song, Cheryn Seo, Seong Il Hong, Sung Kyu Chung, Jinsoo Hong, Sung-Hoo Hwang, Eu Chang Kwak, Cheol Seo, Ill Young Park, Suyeon Park, Chanwang |
author_facet | Park, Jae Young Tae, Bum Sik Jeong, Chang Wook Song, Cheryn Seo, Seong Il Hong, Sung Kyu Chung, Jinsoo Hong, Sung-Hoo Hwang, Eu Chang Kwak, Cheol Seo, Ill Young Park, Suyeon Park, Chanwang |
author_sort | Park, Jae Young |
collection | PubMed |
description | PURPOSE: To develop the clinical calculator for mortality of patients with metastatic renal cell carcinoma (mRCC) using Korean Renal Cancer Study Group (KRoCS) database. MATERIALS AND METHODS: Data from 1,115 patients with mRCC treated in 4 hospitals joining KRoCS between 1993 and 2016 were pooled. Five-year survival rates were calculated using Kaplan–Meier curve. A clinical calculator for 5-year mortality was developed using multivariable logistic regression analysis and validated externally using dataset including 916 patients from 4 other hospitals. RESULTS: Overall survival rates and cancer specific survival rate at 5 years were 28.5% and 29.4%, respectively. Among baseline factors, increased neutrophil-lymphocyte ratio (≥4), synchronous metastasis, low albumin (<3.0 g/dL), and low hemoglobin (<lower limit of normal: male, 13 g/dL; female, 11.5 g/dL) were the significant factors in 5-year mortality. Good internal validity was demonstrated with area under the curve estimates being 0.774 at 5-year mortality calculation and the calibration plot. In the external validation, 758 (82.8%) died by 5 years among these patients, with the average model-predicted rate of 72.9%. CONCLUSIONS: A clinical calculator has been developed to quantify the risk of death for individual patients after treatment of mRCC. This tool may be useful for patients or their guardians who want to know their prognosis and to identify patients requiring aggressive therapy and additional supportive measures during and after treatment. |
format | Online Article Text |
id | pubmed-7189103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Korean Urological Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-71891032020-05-06 Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database Park, Jae Young Tae, Bum Sik Jeong, Chang Wook Song, Cheryn Seo, Seong Il Hong, Sung Kyu Chung, Jinsoo Hong, Sung-Hoo Hwang, Eu Chang Kwak, Cheol Seo, Ill Young Park, Suyeon Park, Chanwang Investig Clin Urol Original Article PURPOSE: To develop the clinical calculator for mortality of patients with metastatic renal cell carcinoma (mRCC) using Korean Renal Cancer Study Group (KRoCS) database. MATERIALS AND METHODS: Data from 1,115 patients with mRCC treated in 4 hospitals joining KRoCS between 1993 and 2016 were pooled. Five-year survival rates were calculated using Kaplan–Meier curve. A clinical calculator for 5-year mortality was developed using multivariable logistic regression analysis and validated externally using dataset including 916 patients from 4 other hospitals. RESULTS: Overall survival rates and cancer specific survival rate at 5 years were 28.5% and 29.4%, respectively. Among baseline factors, increased neutrophil-lymphocyte ratio (≥4), synchronous metastasis, low albumin (<3.0 g/dL), and low hemoglobin (<lower limit of normal: male, 13 g/dL; female, 11.5 g/dL) were the significant factors in 5-year mortality. Good internal validity was demonstrated with area under the curve estimates being 0.774 at 5-year mortality calculation and the calibration plot. In the external validation, 758 (82.8%) died by 5 years among these patients, with the average model-predicted rate of 72.9%. CONCLUSIONS: A clinical calculator has been developed to quantify the risk of death for individual patients after treatment of mRCC. This tool may be useful for patients or their guardians who want to know their prognosis and to identify patients requiring aggressive therapy and additional supportive measures during and after treatment. The Korean Urological Association 2020-05 2020-03-10 /pmc/articles/PMC7189103/ /pubmed/32377601 http://dx.doi.org/10.4111/icu.2020.61.3.260 Text en © The Korean Urological Association, 2020 http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Park, Jae Young Tae, Bum Sik Jeong, Chang Wook Song, Cheryn Seo, Seong Il Hong, Sung Kyu Chung, Jinsoo Hong, Sung-Hoo Hwang, Eu Chang Kwak, Cheol Seo, Ill Young Park, Suyeon Park, Chanwang Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database |
title | Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database |
title_full | Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database |
title_fullStr | Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database |
title_full_unstemmed | Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database |
title_short | Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database |
title_sort | development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: an analysis of patients from korean renal cancer study group database |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189103/ https://www.ncbi.nlm.nih.gov/pubmed/32377601 http://dx.doi.org/10.4111/icu.2020.61.3.260 |
work_keys_str_mv | AT parkjaeyoung developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT taebumsik developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT jeongchangwook developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT songcheryn developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT seoseongil developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT hongsungkyu developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT chungjinsoo developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT hongsunghoo developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT hwangeuchang developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT kwakcheol developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT seoillyoung developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT parksuyeon developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT parkchanwang developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase AT developmentoftheclinicalcalculatorformortalityofpatientswithmetastaticclearcelltyperenalcellcarcinomaananalysisofpatientsfromkoreanrenalcancerstudygroupdatabase |